Skip to main content

Advertisement

SpringerLink
Log in

Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Laryngeal squamous cell carcinoma (LSCC) is one of the most common malignancies in the head and neck region. Recently, aberrantly expressed high-mobility group box 1 (HMGB1) has received a great deal of attention as a potential biomarker for cancer diagnosis and prognosis. Therefore, the aim of this study was to estimate HMGB1 levels in serum in LSCC patients and healthy controls and evaluated the potential of serum HMGB1 as a noninvasive biomarker for diagnosis and prognosis in LSCC. Serum HMGB1 levels were analyzed in 71 LSCC patients and 50 healthy controls. The serum HMGB1 level was significantly higher in LSCC patients compared with the healthy controls (4.81 ± 2.33 vs. 3.21 ± 1.08 ng/mL, P < 0.001). High serum HMGB1 was significantly associated with T classification (P = 0.005), N classification (P = 0.002), and clinical stage (P = 0.001). The area under ROC curve was 0.716, and the sensitivity and specificity were 42.3 and 92.0 %, respectively. The Kaplan–Meier plots showed that patients with high serum HMGB1 had a poorer overall survival than those with low serum HMGB1 (P = 0.036). Serum HMGB1 levels are significantly associated with the progression of LSCC. In this population, HMGB1 has a poor sensitivity, but a high specificity for the diagnosis of LSCC. Serum HMGB1 level has potential as a biomarker for the prognosis in LSCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Ji W, Guan C, Pan Z. Analysis of curative effects on laryngeal carcinoma patients in the northeast region of China. Acta Otolaryngol. 2008;128:574–7.

    Article  PubMed  Google Scholar 

  3. Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev. 2006;32:504–15.

    Article  PubMed  Google Scholar 

  4. Bustin M, Lehn DA, Landsman D. Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta. 1990;1049:231–43.

    Article  CAS  PubMed  Google Scholar 

  5. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 2006;17:189–201.

    Article  CAS  PubMed  Google Scholar 

  6. Czura CJ, Wang H, Tracey KJ. Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res. 2001;7:315–21.

    Article  CAS  PubMed  Google Scholar 

  7. Collins J. First report: prenatal diagnosis of long cord. Am J Obstet Gynecol. 1991;165:1901.

    Article  CAS  PubMed  Google Scholar 

  8. Liu PL, Tsai JR, Hwang JJ, et al. High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol. 2010;43:530–8.

    Article  CAS  PubMed  Google Scholar 

  9. Yang S, Xu L, Yang T, Wang F. High-mobility group box-1 and its role in angiogenesis. J Leukoc Biol. 2014;95:563–74.

    Article  PubMed  Google Scholar 

  10. Livesey KM, Kang R, Zeh HJ 3rd, Lotze MT, Tang D. Direct molecular interactions between HMGB1 and TP53 in colorectal cancer. Autophagy. 2012;8:846–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Evans A, Lennard TW, Davies BR. High-mobility group protein 1(Y): metastasis-associated or metastasis-inducing? J Surg Oncol. 2004;88:86–99.

    Article  CAS  PubMed  Google Scholar 

  12. Qiu Y, Chen Y, Fu X, et al. HMGB1 promotes lymphangiogenesis of human lymphatic endothelial cells in vitro. Med Oncol. 2012;29:358–63.

    Article  CAS  PubMed  Google Scholar 

  13. Zhao CB, Bao JM, Lu YJ, et al. Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res. 2014;4:369–77.

    PubMed Central  PubMed  Google Scholar 

  14. Zhang X, Wang H, Wang J. Expression of HMGB1 and NF-kappaB p65 and its significance in non-small cell lung cancer. Contemp Oncol (Pozn). 2013;17:350–5.

    CAS  Google Scholar 

  15. Liu F, Zhang Y, Peng Z, et al. High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med. 2012;10:135.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Bao G, Qiao Q, Zhao H, He X. Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol. 2010;8:52.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Volp K, Brezniceanu ML, Bosser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 2006;55:234–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Yang GL, Zhang LH, Bo JJ, et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 2012;106:57–61.

    Article  CAS  PubMed  Google Scholar 

  19. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol. 2008;216:167–75.

    Article  CAS  PubMed  Google Scholar 

  20. Liu Y, Xie C, Zhang X, et al. Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer. 2010;46:3007–15.

    Article  CAS  PubMed  Google Scholar 

  21. Chen CG, Tang P. Yu ZT [Effect of HMGB1 on the VEGF-C expression and proliferation of esophageal squamous cancer cells]. Zhonghua Zhong Liu Za Zhi. 2012;34:566–70.

    CAS  PubMed  Google Scholar 

  22. Lee H, Song M, Shin N, et al. Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS ONE. 2012;7:e34318.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Sheng X, Du X, Zhang X, et al. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat Med J. 2009;50:455–64.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Chung HW, Lee SG, Kim H, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med. 2009;7:38.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Naumnik W, Nilklinska W, Ossolinska M, Chyczewska E. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem Cytobiol. 2009;47:703–9.

    Article  CAS  PubMed  Google Scholar 

  26. Liu Y, Xie CL, Qiu YZ, et al. Expression of HMGB1 protein in laryngeal squamous cell carcinoma and its clinical significance. Zhonghua Zhong Liu Za Zhi. 2012;34:132–6.

    CAS  PubMed  Google Scholar 

  27. Tang X, Shen X, Qian X, Gao X. Expressions of HMGB1, MMP-2 and MMP-9 and prognostic alue in human laryngeal carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013;27:181–7.

    CAS  PubMed  Google Scholar 

  28. Liu Y, Qiu Y, Zhang X, et al. The expression and correlation of HMGB1 and VEGF protein in laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011;25:265–9.

    CAS  PubMed  Google Scholar 

  29. Guo Y, Liu Y, Tan PQ, et al. Expressions and clinical significance of high mobility group box-1 mRNA and protein in laryngeal squamous cell carcinoma tissues and serum. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012;47:487–90.

    PubMed  Google Scholar 

  30. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418:191–5.

    Article  CAS  PubMed  Google Scholar 

  31. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–42.

    Article  CAS  PubMed  Google Scholar 

  32. Rasch S, Algul H. A clinical perspective on the role of chronic inflammation in gastrointestinal cancer. Clin Exp Gastroenterol. 2014;7:261–72.

    CAS  PubMed Central  PubMed  Google Scholar 

  33. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010;1799:131–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Schlueter C, Weber H, Meyer B, et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol. 2005;166:1259–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Wake H, Mori S, Liu K, Takahashi HK, Nishibori M. Histidine-rich glycoprotein inhibited high mobility group box 1 in complex with heparin-induced angiogenesis in matrigel plug assay. Eur J Pharmacol. 2009;623:89–95.

    Article  CAS  PubMed  Google Scholar 

  36. Ono M, Torisu H, Fukushi J, Nishie A, Kuwano M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol. 1999;43(Suppl):S69–71.

    Article  CAS  PubMed  Google Scholar 

  37. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J Leukoc Biol. 2002;72:1084–91.

    CAS  PubMed  Google Scholar 

  38. Pallier C, Scaffidi P, Chopineau-Proust S, et al. Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes. Mol Biol Cell. 2003;14:3414–26.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405:354–60.

    Article  CAS  PubMed  Google Scholar 

  40. Wittwer C, Boeck S, Heinemann V, et al. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer. 2013;133:2619–30.

    CAS  PubMed  Google Scholar 

  41. Fahmueller YN, Nagel D, Hoffmann RT, et al. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer. 2013;132:2349–58.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by Grants from National Nature Science Foundation of Liaoning (No. 201202230, No. 201202232).

Conflict of interest

The authors confirm that there are no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, No. 202 Hospital of PLA, Guangrong Street, No. 5, Shenyang, 110003, China

    Guangbin Qiu, Yunhui Li, Zheng Liu, Mengran Wang, Jingjing Ge & Xiaozhong Bai

Authors
  1. Guangbin Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yunhui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zheng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mengran Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jingjing Ge
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaozhong Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaozhong Bai.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qiu, G., Li, Y., Liu, Z. et al. Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma. Med Oncol 31, 316 (2014). https://doi.org/10.1007/s12032-014-0316-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0316-x

Keywords

Search

Navigation